High-quality peptide product: 99.9% pure Sibinipeptide Acetate Ara-290 peptide neuroprotective lyophilized powder (Ara290 peptide raw material powder)

The product introduction of Cagrilintide is as follows:

ARA - 290 is a synthetic peptide derived from erythropoietin (EPO). With a unique structure and function, its chemical formula is C20H24N4O4 and the molecular weight is 388.43 g/mol. It typically appears as a white powder, usually in the form of lyophilized powder in 3 - ml vials, with a purity of ≥99%. For storage, it should be kept at ≤6°C, sealed, and away from heat sources, light, and moisture.

Mechanism of Action

ARA - 290 selectively binds to the innate repair receptor (IRR). IRR belongs to the type I cytokine receptor family, composed of the β common receptor (CD131) and the erythropoietin receptor subunit. When ARA - 290 binds to IRR, it activates a series of intracellular signaling pathways, thereby exerting anti - inflammatory, cytoprotective, and tissue - repair - promoting effects. Unlike EPO, ARA - 290 does not stimulate red blood cell production, thus avoiding serious side effects such as thrombosis, which may occur in the clinical application of EPO.

Efficacy and Functions

1. Anti - inflammatory: ARA - 290 can significantly reduce inflammation - related indicators. For example, it inhibits the release of inflammatory factors such as tumor necrosis factor - α (TNF - α) and interleukin - 6 (IL - 6), effectively reducing the inflammatory response of various tissues and organs in the body, and showing good effects in intervening in chronic inflammatory diseases.

2. Neuroprotection: It protects neurons, enhances the survival ability of nerve cells, and reduces neuronal apoptosis, thus maintaining the normal function of the nervous system. Clinical studies have shown that ARA - 290 helps improve the symptoms of neuropathy. For instance, it relieves the pain caused by diabetic peripheral neuropathy, promotes the regeneration of nerve fibers, and increases nerve conduction velocity.

3. Wound Healing Promotion: By promoting cell proliferation and migration, ARA - 290 accelerates the repair process of damaged tissues, shortens the wound healing time, improves the quality of healing, and reduces the likelihood of scar formation. It has potential application value in skin trauma, surgical wound healing, and other aspects.

4. Immunomodulation: ARA - 290 shows positive effects in the treatment of autoimmune diseases. It can regulate the activity of immune cells, correct abnormal immune responses, and reduce the attack of the immune system on self - tissues. It has demonstrated certain efficacy in the treatment research of diseases such as systemic lupus erythematosus and rheumatoid arthritis.

5. Anti - apoptosis: ARA - 290 can inhibit the activation of the cell apoptosis signaling pathway, enhance the anti - apoptotic ability of cells, protect cells from programmed death caused by various harmful factors, and maintain the normal physiological function and quantity stability of cells.

Clinical Research and Application Prospects

1. Diabetes and Complications: In a Phase 2 clinical trial, 2 - type diabetic patients received a daily subcutaneous  of 4mg ARA - 290 for 28 days. During the subsequent 56 - day observation period, their glycated hemoglobin (HbA1c) and blood lipid levels improved, and symptoms of neuropathy were significantly reduced. This indicates that ARA - 290 has important potential application value in controlling the development of diabetes and relieving diabetic neuropathy, and is expected to become a new drug for the treatment of diabetes and its complications.

2. Sarcoid Neuropathy: A double - blind, randomized, placebo - controlled Phase 2b study on patients with sarcoid neuropathy showed that different doses (1mg, 4mg, 8mg) of ARA - 290 were subcutaneously daily for 28 days. The results showed that the 4mg dose of ARA - 290 significantly increased the corneal nerve fiber area, and the length of growth - associated protein - 43 nerve fibers in the skin epidermis also increased significantly. Patients' pain was relieved and their functional activities improved. This provides a new and effective treatment method and hope for the treatment of sarcoid neuropathy.

3. Renal Ischemia/Reperfusion Injury: In animal experiments, rats and pigs with renal ischemia/reperfusion injury were intervened with ARA - 290. The results showed that ARA - 290 could improve renal function, reduce the inflammatory response and acute kidney injury, increase the glomerular filtration rate, and reduce interstitial fibrosis. This indicates that ARA - 290 has the potential to become a candidate drug for preventing and treating ischemic injury after kidney transplantation, and is expected to improve the success rate of kidney transplantation and the prognosis of patients.

Application Fields

1. Pharmaceutical R & D: As an active peptide with a clear mechanism of action and significant efficacy, ARA - 290 provides an important direction for the research and development of new drugs. Many pharmaceutical companies and research institutions are conducting in - depth research around it, aiming to develop innovative drugs for a variety of refractory diseases.

2. Clinical Treatment: It is applicable to the treatment of diabetes and its complications (such as neuropathy), autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis), nerve injuries (such as traumatic nerve injuries, ischemic nerve injuries), kidney injuries (such as protection before and after kidney transplantation, acute kidney injury), etc., bringing new ideas and methods to the clinical treatment of these diseases.

3. Scientific Research Experiments: ARA - 290 is an important tool for studying basic biological processes such as cytoprotection, inflammatory response, neurobiology, and immunology in the scientific research field, helping researchers to deeply explore the pathogenesis of diseases and therapeutic targets.